FDA approves Idorsia's TRYVIO, a new oral anti-hypertensive therapy targeting endothelin pathway.
FDA approves Idorsia's TRYVIO, the first oral anti-hypertensive therapy in 30+ years, targeting endothelin pathway. Approved for hypertension treatment in combination with other antihypertensive drugs, for adults not adequately controlled by current drugs. TRYVIO is available via restricted program under REMS, and set to launch in the US in H2 2024.
March 20, 2024
4 Articles